On the basis of these unique characteristics of quiescence and high clonogenic potential, the authors contemplated the possibility of CPCs representing a cancer stem cell-like population in myeloma.1 These findings imply that monoclonal antibodies against surface markers like CD38 might not be effective against CPCs. This evidence concerns the gene CD38 and plasma cell myeloma.